Advising Bayer, owner of the innovative cancer drug Nexavar, in court proceedings against local manufacturers, distributing generic versions of the drug prior to the expiry of the original patent. We have protected Bayer’s patent rights, securing a precedent setting victory in the Intellectual Property Court for the German multinational Bayer, overturning previous court rulings in the case.
Advising Novartis in a case against a competitor, which registered a generic drug in the Healthcare Ministry of Russia, while a patent for the original cancer drug was expiring only in 2023. The relevant laws are in fact contradictory and, generally, do not permit preventive lawsuits. The strategy, developed and implemented by EPAM’s and co-counsel’s team resulted in a precedent-making court decision. The judge opined that the conduct of the opponent posed a threat of violation of the clients’ exclusive right to the original drug and compelled the opponent not to commercialize the drug in Russia until after the paten on the drug expires.
Advising one of the leading global pharmaceutical companies on competition law issues including drafting practical recommendations on interaction with distributors in the framework of the supply of medicines for the state needs as well as finalizing the draft of commercial policy and coordinating approval with the Federal Antimonopoly Service of Russia (the FAS Russia).
Conducting a targeted antitrust compliance audit on the supply of a antithrombotic drug upon the request of one of the leading global pharmaceutical companies.
Advising one of the world’s largest pharmaceutical companies on launching a new vaccine in Russia, including advice on public procurement regulations, budgetary financing of medicine procurement, the possibility of procurement of drugs with specified trademarks, etc.;
Representing a leading Asian pharmaceutical and biotech company in the Chamber for Patent Disputes of the Russian Patent and Trademark Office (PTO) in relation to a Russian patent dispute against a competitor.
Advising Hythiam, a leading US healthcare services management company, primarily involved in research, development, licensing and commercializing innovative technology, on setting up clinic operations in Russia and Ukraine, including advertising law issues related to treatment protocols on addictions.
Advising Invitrogen Limited on importation/distribution of biotech products in Russia.
Representing Antiviral, a Russian pharmaceutical company, in the FAS Russia in a case connected with the violation of Competition Law by the client’s competitor, who managed to register a client’s drug name as its trademark.
Advising a US pharmaceutical company on an acquisition, of one of the largest Russian pharma companies including post-merger integration and regulatory support.
Advising a major shareholder of a Russian pharmaceutical group on corporate restructuring and sale of a business unit possessing IP rights to certain trademarks.